Trial Information - Phase III
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure
Disease Specifics: NSCLC
Protocol ID: 61186372NSC3002
Sponsor: Jannsen
Status: STAR Trial
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
